Patients receiving nipocalimab plus standard of care improved by 4.7 points on the MG-ADL score, significantly more than placebo, and that was from baseline over weeks 22, 23, and 24, so around 6 ...

Nipocalimab demonstrates significant long-term efficacy and safety in generalized myasthenia gravis, improving MG-ADL scores and reducing immunoglobulin G levels. The phase 3 Vivacity-MG3 study ...

研究达到主要终点，在24周内，接受nipocalimab治疗患者的gMG疾病指标日常生活活动评分（MG-ADL）获得统计学显著和具有临床意义的改善。值得一提的是 ...

Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and ...

The MG-ADL scale ranges from 0 to 24, with higher scores indicating more severe symptoms. Nipocalimab plus standard of care ...

Nipocalimab-treated patients saw a 4.7-point improvement from baseline in the myasthenia gravis - activities of daily living (MG-ADL) score in weeks 22, 23, and 24 - compared to a 3.25-point ...

This signals the FDA’s recognition of nipocalimab’s potential to address unmet needs among people living with gMG, a chronic autoimmune disease that impacts around 700,000 individuals worldwide.

There was an average 3.7-point fall in the placebo group, which compared to a 6.4-point reduction with a 15 mg/kg dose of nipocalimab given as a biweekly infusion. A lower, 5 mg/kg dose of the ...

The Vivacity-MG3 study met its primary endpoint demonstrating statistically significant and clinically meaningful improvement over 24 weeks in the MG-ADLa score. Nipocalimab had a tolerable safety ...

(RTTNews) - Johnson & Johnson (JNJ), on Thursday announced the publication of new data on nipocalimab, an investigational drug designed to treat IgG-driven alloantibody and autoantibody diseases.